

IFPA
GLOBAL LEADER IN FIGHTING
PSORIATIC DISEASE

IFPA org no 802428-5986

Annual Accounts 2024

Content

Director's Declaration 2024

Founded in 1971, IFPA is the international federation of psoriasis associations. We are the psoriatic disease community. Our members represent over 60 million people living with psoriatic disease. Together, we advocate for progress.

Purpose of the Federation

IFPA is the global voice dedicated to advancing psoriatic disease policy. IFPA is the trusted convener of psoriatic disease stakeholders across sectors and geographies, partnering to strengthen national and regional capacity and leadership. IFPA works with others to generate and share evidence to inform change that can address unmet needs for people living with psoriatic disease.

- **Legitimacy to represent people living with psoriatic disease:** IFPA is the only organization that brings a unified global voice of people living with psoriatic disease to the global agenda.
- **History and track record in the psoriatic disease community:** IFPA has been unifying the psoriatic disease community and has a proven track record of elevating psoriatic disease onto the global agenda.
- **Independence and integrity:** Decisions are exclusively driven by the needs of the people living with psoriatic disease.

Vision

A future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities.

Mission

Unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease.

Goals

Ensure global representation: Boost the voices of everyone living with psoriatic disease, everywhere.

Lead global advocacy: Fight for the interests of people affected by psoriatic disease. Demand representation on global health and development agendas.

Strengthen member capacity: Strengthen IFPA members. Raise national support for people living with psoriatic disease.

Share knowledge: Close the gap between knowledge and action. Trigger breakthroughs for people living with psoriatic disease.

Unite stakeholders: Build alliances. Transform global, regional, and national collaboration.

The interrelated goals are equally important and support each other. The strategic goals are further broken down in different activities with performance indicators set for 2024 and for 2030.

In addition to goals, four core values are identified, as well as a number of priority issues, those cross-cutting issues that influence the strategic goals and vary in relevance and importance. The priority issues identified by IFPA, and its stakeholders, very much reflect the recommendations set out in the WHO Global Report on Psoriasis in 2016.

Values

Person-centered: Ensure that people living with psoriatic disease are at the heart of everything IFPA does.

Collaborative: Work together and openly with members and partners.

Accountable: Be responsible for all actions

Bold: Have the confidence and courage to lead the global psoriatic disease community.

Priority issues

Equal access to treatment, specialists and individualized care: People living with psoriatic disease require access to appropriate treatment and care, including trained healthcare professionals and medicines. However, inadequate access to healthcare is a challenge in many countries across the world.

Early diagnosis of psoriatic disease: People living with psoriatic disease can experience unnecessary suffering, irreversible deformities of the joints and disability due to late diagnosis and lack of appropriate treatment. One standard global guideline to help promote early diagnosis of and appropriate treatment for people living with psoriatic disease.

Making healthcare providers aware of psoriatic disease: Lack of adequate training for healthcare practitioners and providers results in low awareness of psoriatic disease. Increased awareness and understanding of psoriatic disease among those responsible for providing care can help facilitate early diagnosis and appropriate treatment.

Stop stigma: People with psoriatic disease still experience stigmatization and discrimination. Public misconceptions about psoriasis, for example the myth that it is a contagious disease, result in people with psoriatic disease being excluded from everyday life and foster low self-esteem, depression and even suicidal thoughts.

Change the perception of psoriatic disease and call for consensus on categorizing severity: Psoriatic diseases are complex and unpredictable conditions with varied manifestations and associated diseases that affect individuals differently. The misperception that psoriatic disease is a mere skin condition and the lack of consensus on categorizing the severity levels of the condition can lead to inadequate treatment and care.

Multidisciplinary care: People living with psoriatic disease require access to multidisciplinary care to identify and manage common comorbidities that already exist or may develop, including cardiovascular and metabolic diseases (such as diabetes) and psychological conditions. Multidisciplinary care teams include primary care physicians, dermatologists, rheumatologists, psychologists, psychiatrists, pediatricians, cardiologists, and endocrinologists.

Link psoriatic disease and mental health: Psoriatic disease causes great physical, emotional, and social burdens, all of which may impair an individual's quality of life and be psychologically devastating. Increased awareness and focus on the link between psoriatic disease and mental health can help improve quality of life and wellbeing for people living with psoriatic disease.

Join forces with family and community: Psoriatic disease affects relationships at home, school, and work, as well as intimate relationships. Community support, caretakers, and families should be included in the fight against psoriatic disease.

Year 2024

Theme of the year: Family

Psoriatic disease has a severe impact on the lives of those living with the disease. It is estimated that at least 60 million people live with psoriatic disease, but we know that many more are affected by it. In that group, we can include family members, such as parents, siblings, children, partners, and caregivers.

In 2024, IFPA highlighted the important role of the family, caregivers, and partners, also known as the Greater Patient, in the life of those affected by psoriatic disease. Despite several studies reporting a significant burden of psoriatic disease on the family, there is a general lack of understanding of the real impact on their lives. Family and partners not only have an emotional support role but also help with everyday tasks and treatment. This, however, comes with a cost for their own wellbeing that is not discussed enough.

IFPA raised awareness of the wide impact of psoriatic disease and showed initiatives implemented in several countries to improve the quality of life of the Greater Patient. We presented recommendations that could be applied locally and globally to increase awareness of the impact of psoriatic disease in the family, fight stigma, and improve well-being.

The theme acted as a red thread throughout the year, uniting IFPA's advocacy priorities and project choices for the year, as well as World Psoriasis Day.

Everyone navigating the challenges of psoriatic disease deserves unwavering support. This includes recognizing the challenges faced not only by the individual with psoriatic disease but also by their loved ones.

Below follows a description of IFPA's activities and achievements during the year.

Governance

General Assembly

The General Assembly, consisting of IFPA's full Members, is the highest decision-making body of IFPA. The meeting of the General Assembly is held every three years, with the next to be held in 2025.

Extraordinary General Assembly Meeting 2024

The IFPA Board called for a virtual Extraordinary General Assembly to address a gap in the constitution regarding absence of leave for Board Members. The situation arose when IFPA's President, Dr. Hoseah Waweru, asked for a medical leave of absence. Sadly, he passed away before the Extraordinary General Assembly Meeting was held. The General Assembly met online on June 3 and decided to approve the operation of a 6-person Board until the next ordinary General Assembly to be held latest per June 30, 2025.

Board Meetings

In 2024 the IFPA Board had ten (10) Board meetings, of which four (4) were physically conducted.

Secretariat

During 2024 the IFPA Secretariat consisted of the:

- Executive Director
- Finance & Administration Manager
- Marketing & Communications Manager
- Community Manager
- Policy & Advocacy Manager
- Fundraising Manager
- Scientific Officer
- Global Communicator
- Scientific Project Leader – new role

The number of full-time staff positions at the Secretariat was 9 (8).

Members

This year one new member organization was welcomed from United Kingdom. By December 31, 2024, IFPA had 60 national member organizations in 57 countries and 3 regional member organizations.

IFPA Member Meeting 2024

The Member Meeting was held in connection with the IFPA Conference at Waterfront Congress Centre in Stockholm, Sweden, on Sunday, June 30, and brought together 85 onsite patient advocates and psoriatic disease stakeholders from all over the world. The meeting consisted of six sessions:

- Multi-topic Workshop: Engaging Youth, Working with AI, Implementing the Resolution

- Project Speed Dating: 10th anniversary of the Resolution, IFPA Forum, IFPA Accelerator, Family Wellbeing, General Assembly and IFPA Board, Funding Opportunities, Sponsorship and Membership, World Psoriasis Day, Psoriatic Arthritis Awareness Project
- Member Presentations: Turkey, Japan, Taiwan, Kenya, PsorAsia, Collapiel
- Member Portal
- IFPA 2023-2024 Impact Presentation
- 2025 Forum and Theme Announcement

Member Survey

In IFPA's global strategy, 'Strengthen member capacity' is one of the five main goals. It is therefore important for IFPA to continually collect reports from our national and regional members around the world. These surveys help us understand the global impact of our organization on the lives of people living with psoriatic disease. They also influence our strategy for continued improvement of the organization.

The 2024 Member Reporting was conducted December 2024 - January 2025 and organized into three areas:

- Impact Report
- Feedback on 2024
- Input for 2025

31 (42) members reported. Member satisfaction is crucial to IFPA and by 2024 we set out to have a satisfaction rate of 4+ out of 5. The member satisfaction rate for 2024 was 4.3 (4.2).

In addition to the reporting, all members were offered individual calls with the IFPA Community Manager. 24 calls were held.r

More details from the member reporting will be available on the website during spring 2025.

Notable impactful actions by our members in 2024 include a scalp psoriasis training for beauty professionals in Malaysia and South Africa, and a multinational research project in South America called COLLAPIEL.

Member Portal

The Member Portal is a resource to meet the members' needs that is:

- A knowledge hub hosting the latest psoriatic disease research
- A collaborative space for communication between members
- A learning center to continue building capacity and skills
- A place to showcase national work
- A library of resources

In February 2024, IFPA launched a user-friendly community platform. The portal houses a calendar of IFPA events, a library of resources, access to virtual trainings, discussion forums, and virtual working groups for IFPA's different projects. Members have been slowly but steadily entering the platform, with some of IFPA's first organic engagements taking place towards the end of the year. Currently there are 95 people registered in the platform.

Webinars

IFPA Webinars are open live for everyone, and on demand for our members through the IFPA Member Website. One webinar was conducted during 2024. This was a presentation about psoriatic disease and intimacy, which is an often neglected topic that affects a reported 95% of people living with psoriatic disease.

Community Corner

In 2024 we initiated the Community Corner, a series of monthly meetings open to IFPA members. These meetings take place virtually. Instead of the presenter/audience format of a normal webinar, Community Corner is a space discussion. Members share ideas around a specific topic, and IFPA invites interesting guests to facilitate the conversation. Topics so far have included:

- Non-communicable disease advocacy and comorbidities
- Fundraising
- Projects for 2025
- End of year wrap up
- Board roles and general assembly procedures

IFPA Accelerator Program

The Accelerator program is one of our four flagship programs, a training program that supports organizations to expand their work and guides new advocates in establishing patient associations.

The program aims to:

- Accelerate the growth of IFPA
- Leverage the skills and capacities of selected member associations in each region
- Strengthen regional alliances and facilitate best practice sharing within regions

In 2024, trainings were created on the following topics:

- Digital Marketing
- Community Mapping
- Family and Psoriatic Disease
- Storytelling
- General Assembly procedures
- Passing legislation
- How to measure health system's effectiveness

IFPA Funds

With different funds IFPA support efforts worldwide to strengthen patient organization's ability to act. Read more on IFPA Project Funding page.

Dr. Hoseah Waweru Solidarity Fund

The IFPA Solidarity Fund was created to address the funding gap faced by many of IFPA's members, by awarding grants to support advocacy, education and awareness-raising in psoriatic disease. After the passing of IFPA's President in 2024, the Fund was renamed in his memory. This year the Fund had one call for application. 6 out of 16 applying organizations were elected to share 20,500 EUR (250,000 SEK).

- Psoriasis Association of Malaysia – Breathwork (SOMA) program tailored specifically for psoriasis patients, to restore balance and promote overall wellbeing.
- South African Psoriasis Association – Educational materials for beauty practitioners and in-person session with dermatologist and patients about psoriasis.
- Psoriasis Association Ghana – Groundwork for the first Genome-Wide Association Study (GWAS) in Africa, in partnership with the University of Milan and Dr.Giovanni Damiani.
- Psoriasis Association of Kenya – Conduct and publish a study on the prevalence of psoriasis in Kenya.
- Fundapso, Psoriasis Patients Support Foundation, Colombia – Dermatologists, rheumatologists, nutritionists, and psychologists from across Colombia will be invited to the Fundapso national patient congress to discuss the latest treatments, research and comprehensive management of psoriasis.
- The Swedish Psoriasis Association– Investigation on how the healthcare system deals with mental health issues in persons with psoriatic disease, and also measure/survey the patients' experiences.

IFPA Start-Up Fund

The IFPA Start-Up Fund was created in 2023 to support individuals or groups who reside in a country where there doesn't exist a patient association, and who has the ability to start one. For this reason, the Start-Up funding is connected to specific projects, Start-Up projects, with the purpose of starting new patient associations.

In 2024, Start-Up projects were continuing in Afghanistan and Rwanda and initiated in Pakistan.

Project Rare GPP

The Project Rare GPP fund is an opportunity for patient organizations to reach those in their region living with GPP (Generalized Pustular Psoriasis). National patient organizations are crucial to the fight against psoriatic disease and often lack resources to carry out all the projects they wish for. With the financial assistance from this fund, they can realize some of these projects.

During 2024, the Fund had two calls for application, where applying organizations could share a total of 100,000 EUR.

The first round was closed in March, 6 out of 17 project applications were elected:

- Psoriasis Philippines – GPP Network
- Deutscher Psoriasis Bund, Germany – User-friendly online platform for people with GPP
- APAPSO Peru – Awareness raising campaign in Peru
- Epidermia, Greece – It's Time for GPP
- SPOEX, Iceland – GPP in Iceland
- Psoriasis Association Ghana – Advancing research and support for GPP

The second round was closed in August, 6 out of 8 project applications were elected:

- Psoriasis Australia – GPP Care Hub
- Psoriasis- og eksemforbundet, Norway – Helpline, website support and community for GPP patients
- AEPSO, Argentina – Awareness and Support for Patients with GPP
- Autoimmune Disease Patients Association, Romania – Awareness raising of GPP to increase accurate diagnosis
- Psoriasis Association Taiwan – Manual for caregivers of patients with GPP
- Acción Psoriasis, Spain – GPP Companion

Communications

Communication channels

IFPA Update and Newsletters

IFPA continued its internal newsletter, the IFPA Update, to communicate more frequently with members, sending 62 newsletters throughout the year to keep members informed about developing projects and opportunities.

Additionally, IFPA distributed two newsletters to 139 external recipients, including stakeholders, partners, and other key audiences. These newsletters highlighted important updates on the IFPA Conference (7th WPPAC), World Psoriasis Day, and various initiatives planned for 2024.

In support of World Psoriasis Day, IFPA issued 10 dedicated newsletters featuring relevant information and updates. Furthermore, several targeted newsletters were sent separately to provide updates and follow-ups on the IFPA Conference.

Website

Due to changes in Google policies and updates to our analytics software, direct comparisons of data from previous years remain challenging. Additionally, exact data for 2023 is not available. To enhance the accuracy and reliability of our data moving forward, IFPA has been working on improvements to its website. These updates will ensure that, starting in 2025, we can collect and analyze data more precisely, allowing for better tracking of trends and performance over time.

We can provide some analytic insights for 2024. Page views are estimated to be 17,721. The top five countries frequenting the IFPA website being the USA, UK, Sweden, India, and Canada. The most visited web pages include the Homepage, World Psoriasis Day, IFPA Conference, Resources & Tools, and World Psoriasis Day campaign materials, underlining the diverse interests of visitors, from general information to specific events and campaign details.

Social media

In 2024, IFPA focused on creating informative content, fostering meaningful connections, and building engaged communities across our social media platforms.

Key highlights included:

- The release of "Psoriatic Disease and the Family: Navigating Challenges Together", a film exploring the impact of psoriatic disease on families.

- The 10th Anniversary of the World Health Assembly (WHA) Resolution on Psoriasis, marked by the creation of "A Decade of Action Since the World Health Assembly Resolution on Psoriasis", a film celebrating this milestone and showcasing inspiring national success stories.
- World Psoriasis Day campaign initiatives, amplifying awareness and advocacy efforts.
- Live coverage of the IFPA Conference 2024, bringing real-time updates and insights to our global community.

Followers per platform	**2024**	**2023**
LinkedIn	1,942	1,231
Instagram	3,533	3,000
X (Twitter)	6,438	6,431
Facebook	14K	14K
YouTube	567	370
TikTok	895	913

World Psoriasis Day

World Psoriasis Day (WPD) is the annual day dedicated to people living with psoriatic disease. WPD is celebrated on October 29, with the overall aim of:

- Raising awareness about the severity of the disease and the everyday challenges faced by people living with psoriatic disease
- Spreading information about psoriatic disease, refuting common misconceptions and increasing knowledge among people living with the condition
- Improving access to treatment by targeting health ministers, governments and decision-makers
- Creating a united platform to empower people living with psoriatic disease

World Psoriasis Day provides a unique opportunity for IFPA to take action, drive advocacy, and demonstrate leadership among multiple stakeholder groups. IFPA uses World Psoriasis Day to mobilize enthusiasm for a shared theme and goal.

World Psoriasis Day 2024 focused on the theme "Psoriatic Disease and Family," highlighting that psoriatic disease affects not only individuals but also their families, creating challenges that ripple through relationships, work, and daily life. On this day we raised awareness of these shared challenges and offered resources to address the effects on family dynamics, the economy, and social connections, advocating for greater understanding and support. The World Psoriasis Day Impact Report 2024 will be released this spring, offering further insights.

The press release “World Psoriasis Day 2024: Psoriatic Disease and Family- Standing Together in Support and Understanding” had 377.6K recorded views with a potential reach of 3.1B.

Advocacy and Policy

IFPA Coalition

By collaborating across borders, sectors and disease areas, IFPA uses the Coalition to generate support to implement the recommendations outlined in the Global Report on Psoriasis, developed by the World Health Organization in 2016. The Coalition convened four times in 2024: March (virtual), June (in person), September (in person) and December (virtual). During these meetings, the main initiatives in advocacy were discussed, namely:

- The initiatives planned to commemorate the tenth anniversary of the WHA resolution on psoriasis
- The follow-up to the IFPA Forum Asia
- IFPA’s activities and plans with the World Health Organization

Coalition members gave helpful input and contributions to discussions to further amplify IFPA’s advocacy work. In 2024, the IFPA Coalition counted 16 members from civil society, industry, and medical professionals’ organizations.

Resources

IFPA developed and launched several resources and led initiatives linked to the 10th anniversary of the resolution:

- A side-event on the margins of the World Health Assembly titled “A decade of action since the WHA resolution on psoriasis”
- A review of progress since the WHA resolution on psoriasis
- Film and articles on successful examples of policy action after the Resolution
- Session at the IFPA Conference, workshop with members and World Psoriasis Day event in Geneva

Moreover, IFPA collaborated with the World Health Organization and the International Psoriasis Council to publish the course “Psoriasis” on the OpenWHO platform.

Relationship with international policy bodies

IFPA representatives went to Geneva to participate in meetings and side events on the margins of the 77th World Health Assembly. IFPA organized a side event to commemorate the 10th anniversary of the resolution. About 50 people attended the side event and reception.

IFPA followed up on the connection established during 2023 with a representative from the WHO, who then participated in the side-event as a speaker and coordinated the publication of the OpenWHO course “Psoriasis” from the WHO side. IFPA was very active in reaching out to various WHO representatives from different departments to follow up on the call to action put forward in the side event.

IFPA’s network in advocacy

IFPA renewed its membership in the International Alliance of Patients’ Organizations (IAPO), the Global Health Council and the NCD Alliance. IFPA is also a member of the Civil Society Engagement Mechanism for Universal Health Coverage (CSEM), CoNGO and Rare Diseases International.

IFPA participated in the Rare Disease Campaign 2024, providing toolkits on rare diseases to members and sharing awareness through social media. As a voting member of Rare Diseases International, IFPA represented the spectrum of rare psoriatic disease community at the Rare Disease International Meeting in Barcelona 2024. In preparation for the 2025 World Health Assembly (WHA), IFPA was actively supporting the Rare Disease Resolution campaign to enhance global recognition, care, and resources for those affected by rare diseases.

IFPA continued its collaboration with the International Alliance of Dermatology Patient Organizations (IADPO/GlobalSkin) and is member of the IADPO-led World Skin Health Coalition.

IFPA continued the collaboration with the International Psoriasis Council (IPC) and had regular meetings and a few activities together. Together, IFPA and IPC collaborated on the course “Psoriasis” for the OpenWHO platform. IFPA also attended the IPC Think Tank meeting, in London on December 4. The event included a scientific symposium on psoriasis and a 20th Anniversary Celebration Dinner, highlighting IPC’s contributions to education, research, and advocacy in psoriasis care.

IFPA Forum

The IFPA Forum is a Flagship program of IFPA designed to put the needs of people living with psoriatic disease at the center of the policy discourse at the regional level.

IFPA’s second Forum was held in Singapore on July 3, 2023. In February 2024, two resources (the Roadmap for action and the Playbook) were launched as a result of the IFPA Forum Asia. These resources are available in English and Japanese on the IFPA website.

IFPA financed two national projects (in Japan and China) formulated on the themes of the Forum by IFPA member organizations in the two countries. IFPA offered support and tools to the two organizations to carry out the projects throughout 2024.

Preparations for the upcoming IFPA Forum Americas started. It will take place in Bogotá, Colombia, on April 4, 2025.

Science

'Share knowledge' is one of IFPA's strategic goals. By staying informed on the latest research and sharing knowledge IFPA contribute to closing the gap between knowledge and action, which is one of the challenges related to psoriatic disease. This is relevant for treatment and applies to IFPA's priority issues such as timely diagnosis, stigma, discrimination, equality and general understanding.

External science events

IFPA participated in Scientific dermatology and rheumatology conferences during the year. At some conferences we had a booth in the exhibition area. We contributed with lived experience, spoke up for patient centricity, family wellbeing, diversity, holistic care and much more.

AAD Annual Meeting, San Diego, March 8-12
The 2024 Annual Meeting of the American Academy of Dermatology took place in San Diego in March. More than 19,800 registrants showed up at the San Diego Convention Center. IFPA held meetings with all its partners and confirmed speakers for the upcoming IFPA Conference. Marketing material for IFPA Conference was distributed at sessions on psoriatic disease as well as by the Conference President.

EULAR, Vienna, June 12-15
The European League Against Rheumatism (EULAR) Congress at Messe Wien Congress Center had over 12,850 registrations. IFPA took the opportunity to showcase the work and resources we have developed on Psoriatic Arthritis (PsA) and interact with key opinion leaders, EULAR patient engagement teams and delegates at meetings and in the booth. One of IFPA's Ambassadors broadcasted a podcast on Psoriatic Arthritis (PsA) with 200 listeners and 190 downloads.

EADV, Amsterdam, September 25-28
The European Academy of Dermatology and Venereology Congress (EADV) at RAI Amsterdam Convention Centre had over 17,000 delegates. IFPA attended sessions and co-hosted the joint patient booth provided by EADV. Both before and at EADV, IFPA as member of the EADV Task Force actively collaborated to expand patient organization participation at the congress. IFPA held meetings with all its partners and distributed the Acta Dermato-Venereologica edition with IFPA Conference abstracts.

WODC, Barcelona, October 22-25
The 2024 World Orphan Drug Congress in Barcelona was the largest in-person event in its history, bringing together over 1,600 professionals from the rare disease and orphan drug sectors. IFPA played a key role in the congress, delivering a keynote session on "The Use of Real-World Data (RWD) in Orphan Drug Development and Access Pathways - Patient Advocacy".

ACR, Washington DC, November 14-19
American College of Rheumatology (ACR) Convergence took place at the Walter E. Washington Convention Center with more than 10,000 attendees. IFPA had a booth in the

nonprofit area of the exhibition where we showcased the developed work and resources on Psoriatic Arthritis (PsA) and interacted with key opinion leaders in rheumatology.

Psoriasis: from Gene to Clinic, London, December 5-7
The 10th International Congress 'Psoriasis: from Gene to Clinic' was held at Queen Elizabeth II Centre. IFPA had a booth with information and materials about IFPA's work and activities.

IFPA Conference

Established in 2006, the multidisciplinary IFPA Conference, previously known as the World Psoriasis & Psoriatic Arthritis Conference, held every third year, provides a unique, cross-specialty platform. Medical and health professionals present frontline clinical research in dermatology, rheumatology and beyond. IFPA drives global scientific research through the IFPA Conference which has become a cornerstone event for medical and health professionals worldwide.

The 7th IFPA Conference took place at Waterfront Congress Center, in Stockholm, Sweden, on June 27-29, 2024. The conference, under the theme "Uncovering the broad spectrum of psoriatic disease", brought together more than 1,000 delegates from over 75 countries and featured more than 190 abstracts and 50 high-level presentations. Accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the IFPA Conference called for breakthroughs in research that will improve the understanding of all aspects of psoriatic disease, fostering global collaboration among medical professionals, patient organizations, and industry stakeholders.

Scientific Executive Committee:

- Chairperson - Prof. April Armstrong
- Co-Chair in Rheumatology - Prof. Laura Coates
- Co-Chair in Dermatology - Prof. Ulrich Mrowietz
- Secretary - Barbra Bohannan

A press release marketing the Conference in April had 49.1K recorded views and a potential reach of 1.6B. In July, after the Conference, another press release summarizing the success of the conference had 45.8K recorded views and a potential reach of 1.3B.

Following the June conference, key talks were published into the conference proceedings book, which have been peer-reviewed journal, summarizing highlighted topics. The IFPA Conference 2024 marked a significant milestone with the highest number of abstract submissions to date, reflecting groundbreaking research and advancements in the field. These abstracts are now published in Acta Dermato-Venereologica, providing valuable insights into the latest developments.

The Global Psoriasis Atlas (GPA)

The Global Psoriasis Atlas is an international project launched in 2016 by IFPA, International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). It has made incredible progress and is delivered by global experts and an academic project team led by the University of Manchester. The vision is that the GPA will become the leading epidemiological resource globally on psoriasis providing the common benchmark on the burden of psoriasis in all countries and regions throughout the world. The Atlas will seek to: drive continuous improvement in understanding the natural history of psoriasis; uncover how it affects the individual and society; understand how healthcare can be improved for those living with the disease.

The GPA website is the first-ever comprehensive online epidemiological resource database tool. It contains data on the number of psoriasis cases, healthcare data and looks in depth at the experiences and faces behind people living with psoriasis.

In 2024, the Global Psoriasis Atlas (GPA) continued to advance psoriasis research, presenting key study findings at the IFPA Conference. Recent publications and ongoing research projects, including findings from field surveys Greenland and the South Africa SKINSCAPE study, contributed to a deeper understanding of psoriasis prevalence and impact worldwide. GPA together with the team at IFPA also developed layman summaries and infographics to enhance the accessibility of research findings, including a featured study on generalized pustular psoriasis in Malaysia. Throughout the year, discussions on advancing global dermatology research and data sharing initiatives continued at collaborative meetings such as steering committee, funders meetings and Board of Governors.

In 2024, IFPA also contributed to global psoriasis advocacy by developing national Psoriasis Issue Briefs, with an initial focus on the Americas region in preparation for the IFPA Forum 2025. These reports provide a detailed overview of psoriasis prevalence, management, and healthcare challenges in 24 countries. By highlighting gaps in care, treatment access, and policy frameworks, the issue briefs aim to support evidence-based decision-making and strengthen advocacy efforts worldwide.

Further information is available on www.globalpsoriasisatlas.org.

MySkin

In 2024 IFPA continued as a collaborative research partner alongside leading organizations such as the British Dermatological Nursing Group, the National Institute for Health and Care Research, and King’s College London, contributing to MySkin, a longitudinal study seeking to understand disease trajectory and the factors influencing how and why psoriasis changes over time. With the support of IFPA, the study reached out to the patient community every three months to register their disease progression in a self-reporting portal. The project has so far been launched in the UK. Eventually, the study will be expanded to include other parts of the globe as well.

Psoriasis and Beyond

Psoriasis and Beyond is a joint research initiative between IFPA, 16 national psoriasis organizations and Novartis Pharma AG. The study is overseen by a Steering Committee of patient advocates, dermatologists and rheumatologists.

This study project examines people’s understanding of psoriatic disease and its impact on quality of life, the associated comorbidities; cardiovascular disease, diabetes, depression, anxiety, and psoriatic arthritis, and patient-doctor conversations. In 2024, manuscripts focusing on Japan were published as part of the Psoriasis and Beyond study, including "Perspectives of Japanese Patients on Psoriatic Disease Burden: Results From ‘Psoriasis and Beyond,’ the Global Psoriatic Disease Survey”. Now, a total of 15 global study publications with 5 specific country publications for Italy, France India, Japan, and USA are available.

Projects 2024

IFPA Ambassadors

IFPA continuously receive requests to contribute patient testimonials, survey participants, and stars for photo and video assets.

Through the Ambassador Training program IFPA have recruited a group of 16 ambassadors and given them training on advocacy messaging. Aims of the program are to unite a team of skilled ambassadors, reliable and ready to speak up for psoriatic disease and its comorbidities in the global arena. Their expert perspectives boost the diverse needs and experiences of people living with psoriatic disease, everywhere.

In 2024 the Ambassadors:

- Received training on storytelling for advocacy
- Presented their stories at conferences and on panels
- Directed personal initiatives to address family and psoriatic disease
- Appeared in the World Psoriasis Day film highlighting the family impact of psoriatic disease
- Collaborated for World Psoriasis Day
- Attended IFPA Conference
- Served on steering committees and participated in projects with civil society organizations and industry partners to raise awareness of patient priorities globally

All the Colors We Are

IFPA's project addressing diversity and inclusion was launched in November 2022. IFPA Members and Ambassadors from around the world submitted photos of visible psoriatic disease to the virtual library. These images are available for free download to raise awareness of psoriatic disease on every skin. In 2024, the images have been used in multiple publications including the recent Open World Health organization's course on neglected tropical diseases and in IFPA publications.

Psoriatic Arthritis Awareness

The IFPA GoodCare Project's Phase 3 successfully expanded outreach, improved accessibility, and strengthened partnerships to enhance Psoriatic Arthritis (PsA) awareness and support. Key achievements included disseminating educational materials at major events like EULAR, EADV, ACR and IFPA conferences and promotion in global arthritis and pain awareness campaigns, and the project continues to have more social media visibility. . Resources were translated into nine languages, including Turkish, Greek, and Japanese, improving accessibility. Partnerships with rheumatology societies such as (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) GRAPPA and IPC, with the first joint symposium held at the IFPA Conference by GRAPPA and IPC. At the EULAR 2024 podcast downloads with over 200 active listeners across the arthritis conferences and World arthritis day. The campaign onsite podcast has had largest audiences from the U.S., U.K., Austria, Australia, and Sweden. Moving forward, IFPA will deepen collaborations and explore innovative dissemination strategies to further its impact in other countries.

Corporate Partners

In 2024, IFPA received funding from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Takeda and UCB.

The support covered all from IFPA Partnership Program and Flagship programs to various projects and initiatives within science and advocacy to improve the lives of all people affected by psoriatic disease. Project sponsors are revealed under the project description on IFPA's website.

Administration report

The Board of IFPA hereby delivers the annual accounts for the full year of 2024. Regarding the result and financial positions, please refer to the following statements.

Acting President
Ingvar Ágúst Ingvarsson
Reykjavik, Iceland

Interim Vice President
Helen Crawford
Ottawa, Canada

Secretary
Kathleen Gallant
Pittsburgh, USA

Treasurer
Josef de Guzman
Manila, Philippines

Board Member
Silvia Fernandez Barrio
Buenos Aires, Argentina

Board Member
Masanori Okuse
Yokohama, Japan

IFPA 2024
Org no 802428-5986

Profit and loss account

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
Income	SEK	EUR 11,4865	SEK	EUR 11,096
Membership fees	103 549	9 015	103 634	9 340
Rounding- off to whole SEK	3	0	-1	0
IFPA Conference	1 456 070	126 764	0	0
AbbVie	1 343 376	116 953	1 520 554	137 036
Almirall S.A.	1 569 887	136 672	1 260 589	113 608
Amgen	2 170 512	188 962	1 222 730	110 196
Boehringer Ingelheim	3 442 764	299 723	2 262 544	203 906
Bristol-Myers Squibb	1 560 044	135 815	1 243 615	112 078
Eli Lilly	1 190 217	103 619	1 206 722	108 753
Janssen	385 882	33 594	476 284	42 924
LEO Pharma A/S	1 065 093	92 726	1 185 734	106 861
Novartis	626 812	54 569	1 126 297	101 505
Pfizer	685 138	59 647	1 074 312	96 820
Takeda	1 280 488	111 478	463 632	41 784
UCB	3 251 190	283 044	1 954 310	176 127
Other operating income	12 735	1 109	45 199	4 073
Total income	**20 143 759**	**1 753 690**	**15 146 156**	**1 365 010**

Profit and loss account

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
Costs	SEK	EUR 11, 4865	SEK	EUR 11, 096
Outgoing donations	-1 508 817	-131 356	-1 361 496	-122 701
Translations	-192 319	-16 743	-116 410	-10 491
Member education	-195 100	-16 985	-8 612	-776
Office rental agreement	-493 990	-43 006	-371 269	-33 460
Software programs	-271 533	-23 639	-170 679	-15 382
Freight and transport	-604	-53	-3 179	-287
Conference costs	-1 060 733	-92 346	-852 855	-76 861
Travel costs	-1 170 055	-101 864	-1 650 852	-148 779
Refund members	-59 019	-5 138	-303 721	-27 372
Hotel costs	-628 468	-54 714	-1 140 159	-102 754
Food	-49 709	-4 328	-140 384	-12 652
Reimbursement	-177 285	-15 434	-166 289	-14 986
Printing costs	-189 937	-16 536	-235 591	-21 232
PR-Marketing	-1 148 235	-99 964	-1 281 328	-115 477
News service, PR	-349 877	-30 460	-219 893	-19 817
Hospitality	-8 770	-764	-1 760	-159
Gifts	-13 909	-1 211	-7 594	-684
Office material	-96 238	-8 378	-178 117	-16 052
Phone	-52 330	-4 556	-32 455	-2 925
Insurance for the organization	-20 345	-1 771	-16 417	-1 480
Losses on receivables	-663	-58	-289	-26
Honorariums for external	-96 992	-8 444	-208 735	-18 812
Accountant and audit	-73 045	-6 359	-74 011	-6 670
Consultants	-2 551 559	-222 135	-1 976 180	-178 098
Web	-158 951	-13 838	-57 939	-5 222
IT-costs	-69 281	-6 032	-74 268	-6 693
Bank fees	-41 069	-3 575	-49 593	-4 469
Membership fees	-296 946	-25 852	-301 486	-27 171
Other operating expenses	-1 780 995	-155 051	1 652 505	148 928
Staff & Project management	-7 390 086	-643 371	-6 043 632	-544 668
Interest income tax and bank	63 233	5 505	10 366	934
Interest taxes and fees	-3 358	-292	-1 145	-103
Exchange profit/loss	178 132	15 508	63 984	5 766
Total costs	**-19 908 852**	**-1 733 239**	**-15 319 478**	**-1 380 631**

Profit (+) / Loss (-)	**234 906**	**20 451**	**-173 323**	**-15 620**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
20. Income	SEK	EUR 11,4865	SEK	EUR 11, 096
Bank fees	-2 214	-193	-2 465	-222
Exchange profit/loss	104 654	9 111	20 653	1 861
Total costs	**102 440**	**8 918**	**18 188**	**1 639**

30. Governance				
Software Programs	-2 684	-234	0	0
Conference costs	-55 811	-4 859	-19 347	-1 744
Travel costs	-89 432	-7 786	-334 660	-30 160
Hotel costs	-63 414	-5 521	-12 547	-1 131
Food	-13 284	-1 156	-7 655	-690
Reimbursement	-23 632	-2 057	-24 386	-2 198
Printing costs	0	0	-8 127	-732
Gifts	-10 235	-891	-413	-37
Office material	-10 426	-908	0	0
Phone	-8 764	-763	-3 484	-314
Insurance for the organization	-11 666	-1 016	-4 226	-381
Consultants	-64 931	-5 653	-8 752	-789
Bank fees	-317	-28	-332	-30
Membership fees	-25 036	-2 180	-24 838	-2 238
Staff & Project management	-209 408	-18 231	-241 209	-21 738
Exchange profit/ loss	-1 050	-91	566	51
Total costs	**-590 090**	**-51 373**	**-689 411**	**-62 131**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
40. Members	SEK	EUR 11,4865	SEK	EUR 11,096
Outgoing donations	-236 790	-20 615	-198 587	-17 897
Member education	-81 100	-7 060	-8 612	-776
Software programs	-135 405	-11 788	-139 037	-12 530
Conference costs	-387 073	-33 698	-140 816	-12 691
Travel costs	-74 196	-6 459	-139 598	-12 581
Refund members	-32 644	-2 842	-151 853	-13 685
Hotel costs	0	0	-127 394	-11 481
Food	-630	-55	-109 976	-9 911
Reimbursement	-9 097	-792	0	0
Printing costs	-10 125	-881	-2 219	-200
Hospitality	-842	-73	0	0
Gifts	0	0	-483	-44
Office material	-1 000	-87	-138	-12
Phone	-414	-36	-580	-52
Consultants	0	0	-86 844	-7 827
Staff & Project management	-727 014	-63 293	-624 860	-56 314
Exchange profit/loss	608	53	361	33
Total costs	**-1 695 722**	**-147 627**	**-1 730 636**	**-155 969**

45. Accelerator				
Outgoing donations	-9 161	-798	-9 385	-846
Member education	-114 000	-9 925	0	0
Software programs	-11 536	-1 004	0	0
Travel costs	-4 443	-387	0	0
PR-Marketing	-158 128	-13 766	-137 471	-12 389
Web	-1 133	-99	-1 220	-110
Staff & Project management	-192 170	-16 730	-360 400	-32 480
Exchange profit/loss	-884	-77	894	81
Total costs	**-491 453**	**-42 785**	**-507 581**	**-45 744**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
50. Secretariat and Staff	SEK	EUR 11,4865	SEK	EUR 11,096
Office rental agreement	-493 990	-43 006	-371 269	-33 460
Software programs	-15 240	-1 327	-13 200	-1 190
Freight and transport	0	0	-1 251	-113
Conference costs	-92 042	-8 013	-39 247	-3 537
Travel costs	-31 687	-2 759	-6 308	-568
Hotel costs	-9 344	-813	-5 220	-470
Food	-9 591	-835	-2 617	-236
Printing costs	0	0	-3 567	-321
Hospitality	-1 192	-104	0	0
Gifts	-230	-20	0	0
Office material	-83 757	-7 292	-174 988	-15 770
Phone	-38 787	-3 377	-25 766	-2 322
Insurance for the organization	-8 679	-756	-12 191	-1 099
Accountant and audit	-73 045	-6 359	-74 011	-6 670
Consultants	-31 250	-2 721	-5000	-451
IT-costs	-69 281	-6 032	-74 268	-6 693
Bank fees	-38 230	-3 328	-46 795	-4 217
Other operating expenses	318 810	27 755		
Staff & Project management	-1 190 919	-103 680	-1 149 156	-103 565
Interest income tax and bank	63 233	5 505	10 366	934
Interest taxes and fees	-3 358	-292	-1 145	-103
Exchange profit/loss	39 094	3 403	58 105	5 237
Total costs	**-1 769 485**	**-154 049**	**-1 937 527**	**-174 615**

60. Communication				
Software programs	-59 259	-5 159	-9 657	-870
Freight and transport	-262	-23	-288	-26
Printing costs	0	0	-20 406	-1 839
PR-Marketing	-9 283	-808	-67 584	-6 091
News service, PR	-82 348	-7 169	-15 476	-1 395
Web	-154 336	-13 436	-47 850	-4 312
Staff & Project management	-317 248	-27 619	-460 290	-41 483
Exchange profit/loss	647	56	-813	-73
Total costs	**-622 088**	**-54 158**	**-622 363**	**-56 089**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
65. World Psoriasis Day	SEK	EUR 11,4865	SEK	EUR 11,096
Outgoing donations	-10 215	-889	0	0
Translations	0	0	-2 147	-194
Conference costs	-8 956	-780	-129 675	-11 687
Food	-7 877	-686	-1 520	-137
Printing costs	-22 619	-1 969	-83 451	-7 521
PR-Marketing	-144 975	-12 621	-103 547	-9 332
News service, PR	-66 963	-5 830	-64 929	-5 852
Office material	0	0	-222	-20
Honorariums for external	-17 390	-1 514	-27 323	-2 462
Consultants	-17 230	-1 500	-35 214	-3 174
Web	-324	-28	-4 260	-384
Staff & Project management	-583 302	-50 782	-499 999	-45 061
Exchange profit/loss	946	82	-1 761	-159
Total costs	**-878 903**	**-76 516**	**-954 048**	**-85 981**

70. Advocacy & Policy				
Conference costs	-104 361	-9 086	0	0
Travel costs	-35 139	-3 059	-102 670	-9 253
Hotel costs	-53 856	-4 689	-146 519	-13 205
Food	0	0	-1 441	-130
Reimbursement	-4 942	-430	-20 016	-1 804
PR-Marketing	0	0	-95 334	-8 592
Newsservice, PR	-41 386	-3 603	0	0
Hospitality	-1 884	-164	-1 658	-149
Phone	0	0	-987	-89
Membership fees	-271 910	-23 672	-276 648	-24 932
Staff & Project management	-851 068	-74 093	-469 267	-42 292
Exchange profit/loss	-3 424	-298	1 370	123
Total costs	**-1 367 970**	**-119 094**	**-1 113 169**	**-100 322**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
71. IFPA Forum	SEK	EUR 11,4865	SEK	EUR 11,096
Translations	0	0	-103 213	-9 302
Freight and transport	0	0	-1 641	-148
Conference costs	0	0	-168 561	-15 191
Travel costs	0	0	-266 561	-24 023
Refund members	0	0	-151 867	-13 687
Hotel costs	0	0	-257 468	-23 204
Printing costs	0	0	-67 351	-6 070
News service, PR	-25 255	-2 199	-22 317	-2 011
Gifts	0	0	-5 569	-502
Office material	0	0	-1 255	-113
Phone	0	0	-336	-30
Honorariums for external	0	0	-6 941	-626
Consultants	-417 585	-36 354	-439 801	-39 636
Web	-648	-56	-1 220	-110
Staff & Project management	0	0	-342 247	-30 844
Exchange profit/loss	2 131	185	-876	-79
Total costs	**-441 357**	**-38 424**	**-1 837 224**	**-165 575**

75. IFPA Coalition				
Translations	0	0	-9 921	-894
Conference costs	-12 021	-1 047	-31 325	-2 823
Travel costs	-198 717	-17 300	-218 945	-19 732
Hotel costs	-92 434	-8 047	-67 456	-6 079
Food	-2 217	-193	-1 752	-158
Reimbursement	-23 162	-2 016	0	0
Printing costs	0	0	-19 639	-1 770
PR-Marketing	-24 750	-2 155	0	0
News service, PR	0	0	-117 171	-10 560
Office material	0	0	-100	-9
Phone	-417	-36		
Consultants	0	0	-1 051 690	-94 781
Web	-324	-28	-211	-19
Staff & Project management	-240 813	-20 965	-122 804	-11 067
Exchange profit/loss	-1	0	-6 845	-617
Total costs	**-594 855**	**-51 787**	**-1 647 857**	**-148 509**

Costs per activity

	2024-01-01 2024-12-31		2023-01-01 2023-12-31	
80. Science	SEK	EUR 11,4865	SEK	EUR 11,096
Software programs	-1 267	-110	-1257	-113
Conference costs	-277 074	-24 122	-148 155	-13 352
Travel costs	-292 151	-25 434	-523 882	-47 214
Hotel costs	-286 049	-24 903	-459 689	-41 428
Food	-6 613	-576	-15 211	-1 371
Reimbursement	-84 622	-7 367	-121 886	-10 985
Printing costs	-16 452	-1 432	0	0
PR-Marketing	-4 398	-383	0	0
Hospitality	-1 603	-140	-102	-9
Office material	-133	-12	-479	-43
Phone	-968	-84	-1 301	-117
Web	-324	-28	-236	-21
Staff & Project management	-1 367 821	-119 081	-570 161	-51 384
Exchange profit/loss	-1 886	-164	-697	-63
Total costs	**-2 341 361**	**-203 836**	**-1 843 056**	**-166 101**

85. IFPA Conference / WPPAC				
Software programs	-46 142	-4 017	-7 529	-679
Conference costs	-10 689	-931	-141 843	-12 783
Travel costs	-155 688	-13 554	0	0
Refund members	-26 375	-2 296	0	0
Hotel costs	16 279	1 417	0	0
Food	-2 229	-194	-212	-19
Reimbursement	-9 097	-792	0	0
Printing costs	-18 019	-1 569	-23 911	-2 155
PR-Marketing	-2 360	-205	-4 125	-372
News service, PR	-133 925	-11 659	0	0
Hospitality	-1 662	-145	0	0
Office material	-336	-29	-936	-84
Phone	-414	-36	0	0
Consultants	-153 750	-13 385	-135 159	-12 181
Web	-1 864	-162	-2 941	-265
Other operating expenses	-1 558 220	-135 657	930 298	83 841
Staff & Project management	0	0	-612 270	-55 179
Exchange profit/loss	342	30	-1 372	-124
Total costs	**-2 104 149**	**-183 185**	**0**	**0**

Costs per activity

90. Projects	2024-01-01 2024-12-31 SEK	EUR 11,4865	2023-01-01 2023-12-31 SEK	EUR 11,096
Outgoing donations	-1 252 651	-109 054	-1 153 524	-103 959
Translations	-192 319	-16 743	-1 129	-102
Freight and transport	-342	-30	0	0
Conference costs	-112 705	-9 812	-33 887	-3 054
Travel costs	-288 601	-25 125	-58 228	-5 248
Hotel costs	-139 651	-12 158	-63 866	-5 756
Food	-7 269	-633	0	0
Reimbursement	-22 734	-1 979		
Printing costs	-122 722	-10 684	-6 919	-624
PR-Marketing	-804 342	-70 025	-873 267	-78 701
Hospitality	-1 587	-138		
Gifts	-3 444	-300	-1 129	-102
Office material	-586	-51	0	0
Phone	-2 566	-223		
Losses on receivables	-663	-58	-289	-26
Honorariums for external	-79 602	-6 930	-174 471	-15 724
Consultants	-1 866 813	-162 522	-213 719	-19 261
Bank fees	-308	-27		
Other operating expenses	-541 585	-47 150	722 207	65 087
Project management	-1 710 323	-148 898	-590 969	-53 260
Exchange profit/loss	36 955	3 217	-5 603	-505
Total costs	**-7 113 858**	**-619 323**	**-2 454 794**	**-221 232**

Balance sheet

		2024-01-01 2024-12-31		2023-01-01 2023-12-31	
Bank assets and claims	**Note**	SEK	EUR 11,4865	SEK	EUR 11,096
Outstanding claims	1	1 593 825	138 756	3 853 093	347 251
Other claims		319 118	27 782	652	59
Prepaid expenses and accrued income	2	284 061	24 730	2 366 307	213 258
Cash		1 444	126	2 665	240
Bank Nordea		15 102 352	1 314 791	8 004 726	721 406
Total bank assets and claims		**17 300 799**	**1 506 185**	**14 227 443**	**1 282 214**

		2024-01-01 2024-12-31		2023-01-01 2023-12-31	
Capitals and creditors	**Note**	SEK	EUR 11,4865	SEK	EUR 11,096
Capital		9 095 600	791 851	9 268 922	835 339
Profit or loss		234 906	20 451	-173 323	-15 620
Outstanding debts		95 895	8 348	174 346	15 713
Other debts		1 326 382	115 473	1 225 801	110 472
Prepaid income	3	5 346 343	465 446	2 620 141	236 134
Accrued costs and fees paid in advance	4	1 201 674	104 616	1 111 555	100 176
Total capital and creditors		**17 300 799**	**1 506 185**	**14 227 443**	**1 282 214**

Notes

		2024-01-01 2024-12-31		2023-01-01 2023-12-31	
		SEK	EUR 11,4865	SEK	EUR 11,096
Note 1 Outstanding claims					
Eli Lilly		1 318 188	114 760	0	0
Almirall		207 912	18 101	697 146	62 829
Takeda		57 917	5 042	0	0
UCB Biopharma		8 475	738	1 844 425	166 224
Boehringer Ingelheim		1 333	116	3 200	288
Amgen		0	0	1 295 566	116 760
Bristol Myers Squibb		0	0	9 372	845
OPEN Health Communications		0	0	3 384	305
Total		**1 593 825**	**138 756**	**3 853 093**	**347 251**

Notes

		2024-01-01 2024-12-31		2023-01-01 2023-12-31	
		SEK	EUR 11,4865	SEK	EUR 11,096

Note 2 Prepaid expenses and accrued income

Prepaid expenses

Helioworks Slottsbacken		116 455	10 138	108 750	9 801
StellarUp		50 655	4 410	0	0
AIG Europe		12 598	1 097	11 666	1 051
Prepaid membership fee GHC 2025		10 960	954	10 896	982
Lisa Technologies		8 120	707	3 959	357
Learnifier		4 313	375	4 375	394
Scrive		2 681	233	2 063	186
Fortnox		2 490	217	2 105	190
Söderberg & Partners Insurance Consulting		1 456	127	1 403	126
Loopia		893	78	0	0
Prepaid cost IFPA Conference (2022-2023)		0	0	1 558 220	140 431
Tranås Resebyrå		0	0	85 464	7 702
Prepaid cost Project Rare GPP		0	0	31 171	2 809
Ticketmaster		0	0	13 120	1 182
Prepaid membership fee IAPO 2024		0	0	4 389	396
Republic Factory		0	0	1 500	135
		210 620	*18 336*	*1 839 081*	*165 743*

Accrued income

Nordea Bank Abp		62 820	5 469	9 728	877
NH Collection Hotel Rome		8 941	778	0	0
Camp Ripan		1 680	146	0	0
EUROPSO		0	0	221 500	19 962
Psoriasispatiënten Nederland		0	0	130 766	11 785
SAPSA South Africa		0	0	72 828	6 563
FUNDAPSO Colombia		0	0	59 796	5 389
Shepard Exposition		0	0	20 524	1 850
Europeiska ERV		0	0	12 083	1 089
		73 440	*6 394*	*527 226*	*47 515*
Total		**284 061**	**24 730**	**2 366 307**	**213 258**

Notes

		2024-01-01 2024-12-31		2023-01-01 2023-12-31	
		SEK	EUR 11,4865	SEK	EUR 11,096

Note 3 Prepaid income

UCB Biopharma		1 320 660	114 975	1 224 190	110 327
Amgen		1 111 571	96 772	1 048 227	94 469
Takeda Pharmaceuticals		262 845	22 883	347 724	31 338
Janssen		1 333 080	116 056	0	0
Eli Lilly		1 318 188	114 760	0	0
Total		**5 346 343**	**465 446**	**2 620 141**	**236 134**

Note 4 Accrued costs and fees received in advance

Accrued costs

Accrued cost IFPA Projects		980 031	85 320	870 205	78 425
Grant Thornton		93 750	8 162	0	0
Hummelkläppen		52 500	4 571	51 000	4 596
Collectum		30 837	2 685	0	0
Firstcard		15 040	1 309	18 556	1 672
AEPSO, Argentina		10 442	909	0	0
Travel reimbursements IFPA Board		5 083	443	13 243	1 193
Tele2		3 096	270	2 601	234
Nordea Bank Abp		2 949	257	4 886	440
Helioworks Slottsbacken		2 703	235	2 938	265
Republic Factory		1 500	131	0	0
Staff outlays		1 000	87	0	0
Fortnox		409	36	359	32
Last Mile		0	0	112 558	10 144
Iriam Productions		0	0	30 000	2 704
Italy membership fee 2022		0	0	472	43
		1 199 341	*104 413*	*1 106 818*	*99 749*

Fees received in advance

Vietnam 2025		574	50	0	0
Russia 2025		568	49	0	0
Argentina 2025		531	46	0	0
Uruguay 2025-2026		413	36	620	56
Kenya 2025		247	22	494	45
Israel 2024		0	0	3 347	302
Indonesia 2024		0	0	277	25
		2 333	*203*	*4 737*	*427*
Total		**1 201 674**	**104 616**	**1 111 555**	**100 176**

Signatures

Stockholm, March 24, 2025

Ingvar Ágúst Ingvarsson

Ingvar Ingvarsson
Acting President

Helen Crawford
Interim Vice President

Kathleen L. Gallant

Kathleen L Gallant
Secretary

Josef de Guzman
Treasurer

Silvia Fernandez Barrio
Board Member

Masanori Okuse

Masanori Okuse
Board Member

My auditor’s report has been issued on March 24, 2025

Hummelkläppen i Stockholm AB

Tommy

Tommy Nilsson
Authorized Public Accountant

Verification

Transaction 09222115557542092966

Document

IFPA Annual Accounts 2024
Main document
33 pages
Initiated on 2025-03-20 14:17:58 CET (+0100) by Ida Mourujärvi (IM)
Finalised on 2025-03-24 11:22:06 CET (+0100)

Initiator

Ida Mourujärvi (IM)
IFPA
Company reg. no. 802428-5986
ida.mourujarvi@ifpa-pso.com
+46736635251

Signatories

Ingvar Ágúst Ingvarsson (IÁI)
IFPA
ingvar.ingvarsson@ifpa-pso.com

Ingvar Ágúst Ingvarsson

Signed 2025-03-20 21:24:43 CET (+0100)

Kathleen L Gallant (KLG)
IFPA
kathleen.gallant@ifpa-pso.com

Kathleen L. Gallant

Signed 2025-03-21 12:17:28 CET (+0100)

Josef de Guzman (JdG)
IFPA
josef.deguzman@ifpa-pso.com

Signed 2025-03-22 11:55:10 CET (+0100)

Silvia Fernandez Barrio (SFB)
IFPA
silviafb@ifpa-pso.com

Signed 2025-03-22 11:17:07 CET (+0100)

Verification

Transaction 09222115557542092966

Masanori Okuse (MO)
IFPA
masanori.okuse@ifpa-pso.com

Masanori Okuse

Signed 2025-03-22 13:54:55 CET (+0100)

Helen Crawford (HC)
IFPA
helen.crawford@ifpa-pso.com

Signed 2025-03-22 20:31:17 CET (+0100)

Tommy Nilsson (TN)
Hummelkläppen i Stockholm AB
tommy.nilsson@hummelklappen.se

Signed 2025-03-24 11:22:06 CET (+0100)

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: https://scrive.com/verify